Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will provide an overview of the challenges and offer solutions for the application of next-generation technologies in the production of ADCs and oligonucleotide conjugates. Attendees will learn about the complexities of ADC construction and bioconjugate drug development with a particular focus on the emerging class of oligonucleotide conjugates.

As AOC therapeutic drug development grows, there is a need to for robust, reproducible, and well-defined scale–up and manufacture processes to generate well characterised material for clinical trials

Antibody-drug conjugates (ADCs) are an established class of biopharmaceuticals with therapeutic applications in oncology and beyond. Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the antibody’s exquisite targeting ability and improved biodistribution profile. This approach significantly broadens the therapeutic potential of oligonucleotide-based drugs.

Oligonucleotides, as drug molecules, suffer from several drawbacks such as instability, impaired pharmacokinetics (PK), poor cellular uptake and sub-optimal tissue targeting. Chemical modification of oligonucleotides is therefore frequently required to transform a base sequence into a viable medicine.

As AOC therapeutic drug development grows, there is a need to for robust, reproducible, and well-defined scale–up and manufacture processes to generate well characterised material for clinical trials. While the process development challenges of ADCs are focused on maximizing the loading of drug molecules to the antibody and minimizing the release of free payload, AOC development and manufacture has its own set of unique challenges.

In this webinar, panelists will review oligonucleotide bioconjugates focusing upon their design, development, analysis and manufacture. Case studies which illustrate the chemical processes used in oligonucleotide conjugation and the analytics required to support development and manufacture will be presented.

Join expert speakers from Abzena, Dr. Campbell Bunce, PhD, Chief Scientific Officer; Dr. Matthew Bird, PhD, Scientific Fellow; and Dr. Juan Carlos Cordova, Principal Scientist, in a live webinar on Thursday, February 18, 2021 at 10am EST (3pm GMT/UK) to learn more about the drug development applications of oligonucleotide conjugation and hear case studies which illustrate the chemistry used to overcome challenges in their construction.

For more information, or to register for this event, visit Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website